The release of "Interpretation of National Drug Policy" aims to promote drug research and development innovation, improve market access efficiency and ensure people's drug safety. Specifically, the policy stipulates the following aspects: First, in drug research and development, the policy emphasizes supporting and guiding enterprises to strengthen drug innovation and research and development, and puts forward a series of measures, including encouraging enterprises to make rational use of preferential policies, strengthening drug technology transfer, and supporting independent drug innovation. Secondly, in terms of examination and approval, the policy defines the "green channel" policy, improves the early warning mechanism of patent leakage risk, encourages cross-regional joint examination and approval, strengthens spot checks, and improves the efficiency and accuracy of examination and approval. Finally, in terms of drug supply security, the policy stipulates measures such as strengthening public procurement, improving circulation supervision and improving drug inspection and testing to ensure drug quality and supply. The implementation of these policies and measures will promote the innovation of drug research and development, improve the efficiency of market access and ensure the safety of people's medication. At the same time, it is also conducive to comprehensively promoting the transformation and upgrading of China's pharmaceutical industry and achieving the strategic goal of "healthy China".
Interpretation of national drug policy: Why should drug review and approval be strengthened? Strengthening drug review and approval aims to improve the efficiency and accuracy of drug access and speed up the time to market, so as to better meet the people's drug demand. At the same time, it is also to promote drug research and innovation and enhance the competitiveness of China's pharmaceutical industry.
The release of Interpretation of National Drug Policy provides important policy support for promoting drug research and innovation, improving market access efficiency and ensuring people's drug safety. It is conducive to speeding up the time of drug review and approval, and promoting the high-quality development of China's pharmaceutical industry and the whole economy.
Legal basis:
Article 1 of the Constitution of People's Republic of China (PRC) People's Republic of China (PRC) is a socialist country under the people's democratic dictatorship led by the working class and based on the alliance of workers and peasants. The socialist system is the fundamental system of the people of China. The leadership of China's * * * production party is the most essential feature of Socialism with Chinese characteristics. No organization or individual is allowed to undermine the socialist system. Article 65 The NPC Standing Committee is composed of the following personnel: chairman, vice-chairmen, secretary-general and members. Among the members of the NPC Standing Committee, there should be an appropriate number of minority representatives. The National People's Congress elects and has the right to recall the members of the NPC Standing Committee. Members of the NPC Standing Committee shall not hold the posts of state administrative organs, supervisory organs, judicial organs and procuratorial organs.